Inhalation by design: dual pharmacology β-2 agonists/M3 antagonists for the treatment of COPD

LH Jones, H Baldock, ME Bunnage, J Burrows… - Bioorganic & medicinal …, 2011 - Elsevier
This paper describes the successful design and development of dual pharmacology β-2
agonists-M3 antagonists, for the treatment of chronic obstructive pulmonary disorder using …
被引用次数：24 相关文章

Inhalation by design: Dual pharmacology β-2 agonists/M3 antagonists for the treatment of COPD

LH Jones, H Baldock, ME Bunnage, J Burrows… - Bioorganic & Medicinal …, 2011 - infona.pl
This paper describes the successful design and development of dual pharmacology β-2
agonists-M3 antagonists, for the treatment of chronic obstructive pulmonary disorder using …

Inhalation by design: dual pharmacology β-2 agonists/M3 antagonists for the treatment of COPD.

LH Jones, H Baldock, ME Bunnage… - Bioorganic & …, 2010 - europepmc.org
This paper describes the successful design and development of dual pharmacology β-2
agonists-M3 antagonists, for the treatment of chronic obstructive pulmonary disorder using …

[引用][C] Inhalation by design: Dual pharmacology β-2 agonists/M3 antagonists for the treatment of COPD

LH JONES, H BALDOCK, L HILTON… - Bioorganic & …, 2011 - pascal-francis.inist.fr
Inhalation by design: Dual pharmacology β-2 agonists/M3 antagonists for the treatment of
COPD CNRS Inist Pascal-Francis CNRS Pascal and Francis Bibliographic Databases …

Inhalation by design: dual pharmacology β-2 agonists/M3 antagonists for the treatment of COPD

LH Jones, H Baldock, ME Bunnage… - Bioorganic & …, 2011 - pubmed.ncbi.nlm.nih.gov
This paper describes the successful design and development of dual pharmacology β-2
agonists-M3 antagonists, for the treatment of chronic obstructive pulmonary disorder using …

[引用][C] Inhalation by design: Dual pharmacology β-2 agonists

LH JONES, H BALDOCK, ME BUNNAGE… - Bioorganic & medicinal …, 2011 - Elsevier